| Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes with ring sideroblasts |
|
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
|
National Cancer Institute |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
|
PDQ Cancer Information Summaries |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic Syndromes Treatment (PDQ®): Health Professional Version |
|
PDQ Cancer Information Summaries |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
